Jefferies Backs Relmada, BTIG Turns Bullish on Invivyd
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
/ 2 items
Jefferies and BTIG start coverage on Relmada and Invivyd with Buy ratings, citing pipeline shifts, strong assets, and large market potential.
Mizuho upgrades Relmada Therapeutics to Outperform, raising the price target to $10. NDV-01 shows promise in bladder cancer with $2B peak sales potential.